Search results
Search for "valsartan" in Full Text gives 8 result(s) in Beilstein Journal of Organic Chemistry.
One-pot Ugi-azide and Heck reactions for the synthesis of heterocyclic systems containing tetrazole and 1,2,3,4-tetrahydroisoquinoline
- Jiawei Niu,
- Yuhui Wang,
- Shenghu Yan,
- Yue Zhang,
- Xiaoming Ma,
- Qiang Zhang and
- Wei Zhang
Beilstein J. Org. Chem. 2024, 20, 912–920, doi:10.3762/bjoc.20.81
- ; Introduction Tetrazole is a privileged heterocycle existing in a range of biological and medicinally interesting compounds [1][2] with antifungal [3][4], antibacterial [5], anticancer [6][7], antiparasitic [8], and antihypertensive properties [9] including FDA approved drugs such as valsartan and cefmetazole
Graphical Abstract
Figure 1: Representative bioactive tetrazole- and tetrahydroisoquinoline-containing compounds.
Scheme 1: The Ugi and Ugi-azide reactions.
Scheme 2: Ugi-azide and post-condensation reactions for the synthesis of various heterocyclic scaffolds.
Scheme 3: One-pot synthesis of tetrazolyl-1,2,3,4-tetrahydroisoquinoline.
Scheme 4: One-pot synthesis of tetrazolo-pyrazino[2,1-a]isoquinolin-6(5H)-ones 6.
Scheme 5: One-pot synthesis for tetrazolyl-1,2,3,4-tetrahydroisoquinolines 8.
Scheme 6: Gram-scale two-step one-pot synthesis of 6c.
Figure 2: ORTEP diagrams of compound 6d (left) [CCDC: 2164364] and 8c (right) [CCDC: 2321622].
(Bio)isosteres of ortho- and meta-substituted benzenes
- H. Erik Diepers and
- Johannes C. L. Walker
Beilstein J. Org. Chem. 2024, 20, 859–890, doi:10.3762/bjoc.20.78
Graphical Abstract
Figure 1: Scaffolds commonly reported as bioisosteric replacements of para-substituted benzene and examples p...
Figure 2: 1,2-BCPs as isosteres for ortho-and meta-substituted benzenes: comparison of reported exit vector p...
Scheme 1: 1,2-Disubstituted bicyclo[1.1.1]pentanes as isosteres of ortho-substituted benzenes. A: Baran, Coll...
Scheme 2: Synthesis of 1,2-BCPs from BCP 15 by bridge C–H bromination as reported by MacMillan and co-workers ...
Figure 3: Comparative physicochemical data of telmisartan, lomitapide and their BCP isosteres [26,33]. Shake flask d...
Figure 4: 1,2-Disubstituted bicyclo[2.1.1]hexanes as isosteres of ortho-benzenes: Exit vector parameters of t...
Scheme 3: Synthesis of 1,2-disubstituted bicyclo[2.1.1]hexanes via alkene insertion into bicyclo[1.1.0]butane...
Scheme 4: Synthesis of 1,2-disubstituted bicyclo[2.1.1]hexanes via intramolecular crossed [2 + 2] cycloadditi...
Figure 5: Comparison of physicochemical data of fluxapyroxad and boscalid and their 1,2-BCH bioisosteres [36]. Sh...
Figure 6: Antifungal activity of fluxapyroxad, its 1,5-BCH bioisostere (±)-55, boscalid and its bioisostere 1...
Figure 7: 1,5-Disubstituted bicyclo[2.1.1]hexanes as isosteres of ortho-substituted benzenes. Comparison of e...
Scheme 5: Synthesis of 1,5-disubstituted bicyclo[2.1.1]hexanes as isosteres of ortho-benzenes via intramolecu...
Figure 8: Comparison of physicochemical data of fluxapyroxad and boscalid and their 1,5-BCH bioisosteres [45]. Sh...
Figure 9: Antifungal activity of fluxapyroxad, its 1,5-BCH bioisostere (±)-64, boscalid and its bioisostere 1...
Figure 10: 1,5-Disubstituted 3-oxabicylco[2.1.1]hexanes as isosteres for ortho-benzenes: Comparison of exit ve...
Scheme 6: Synthesis of 1,5-disubstituted 3-oxabicyclo[2.1.1]hexanes as isosteres for ortho-benzenes via intra...
Figure 11: Comparison of physicochemical data of fluxapyroxad and boscalid and their 3-oxa-1,5-BCH bioisostere...
Figure 12: Antifungal activity of fluxapyroxad and boscalid and their 3-oxa-1,5-BCH bioisosteres (±)-75 and (±...
Figure 13: 1,2-Disubstituted bicyclo[3.1.1]heptanes as isosteres of ortho-benzenes. Schematic representation o...
Scheme 7: Synthesis of 1,2-disubstituted bicyclo[3.1.1]heptanes as isosteres for ortho-benzenes via alkene in...
Figure 14: 1,2-Disubstituted stellanes as ortho-benzene isosteres: Comparison of selected exit vector paramete...
Scheme 8: Synthesis of 1,2-disubstituted stellanes as isosteres for ortho-benzenes reported by Ryabukhin, Vol...
Figure 15: 1,2-Disubstituted cubanes as ortho-benzene isosteres: Comparison of substituent distances and angle...
Scheme 9: Synthesis of 1,2-disubsituted cubanes as isosteres for ortho-benzenes. A: Synthesis of 1,2-cubane d...
Figure 16: 1,3-Disubstituted bicyclo[2.1.1]hexanes as isosteres of meta-benzenes: comparative exit vector para...
Scheme 10: Synthesis of 1,3-disubstituted bicyclo[2.1.1]hexanes as isosteres for meta-benzenes reported by Wal...
Figure 17: 1,4-Disubstituted bicyclo[2.1.1]hexanes as isosteres of meta-benzenes: comparative exit vector para...
Scheme 11: Synthesis of 1,4-disubstituted bicyclo[2.1.1}hexanes as isosteres for ortho-benzenes via intramolec...
Figure 18: 1,4-Disubstituted-2-oxabicyclo[2.1.1]hexanes as meta-benzene isosteres: comparison of selected exit...
Scheme 12: Synthesis of 1,4-disubstituted 2-oxabicyclo[2.1.1]hexanes as isosteres for meta-benzenes. A: Mykhai...
Figure 19: Comparative physicochemical data for 2- and 3-oxa-1,4-BCHs and para-substituted benzene equivalents...
Figure 20: 1,5-Disubstituted bicyclo[3.1.1]heptanes as isosteres of meta-benzenes: comparison of exit vector p...
Scheme 13: Synthesis of [3.1.1]propellane as a precursor for 1,5-disubsituted bicyclo[3.1.1]heptanes. A: aGass...
Scheme 14: Synthesis of iodine-substituted 1,5-disubstituted bicyclo[3.1.1]heptanes as isosteres for meta-benz...
Scheme 15: Synthesis of nitrogen-, chalcogen- and tin-substituted 1,5-disubstituted bicyclo[3.1.1]heptanes as ...
Figure 21: Comparative physicochemical data of URB597 and 1,5-BCHep isostere 146 [27]. Kinetic aqueous solubility ...
Figure 22: [2]-Ladderanes as isosteres of meta-benzenes: comparison of reported exit vector parameters [63].
Scheme 16: Synthesis of cis-2,6-disubstituted bicyclo[2.2.0]hexanes as isosteres for meta-benzenes. A: Brown a...
Figure 23: Comparative physicochemical data of meta-benzene 158 and [2]-ladderane isostere 159 [63]. Partition coe...
Figure 24: 1,3-Disubstituted cubanes as isosteres of meta-benzenes: comparison of selected exit vector paramet...
Scheme 17: Synthesis of 1,3-disubsituted cubanes as isosteres for meta-benzenes. A: MacMillan and co-workers’ ...
Figure 25: Comparative physicochemical data of lumacaftor and its 1,3-cubane bioisostere 183 [51]. Distribution co...
Figure 26: 1,3-Disubstituted cuneanes as isosteres of meta-benzenes: comparison of selected exit vector parame...
Scheme 18: Synthesis of 1,3-cuneanes as isosteres of meta-benzene. A: Synthesis of 1,3-cuneanes reported by La...
Figure 27: Comparative physicochemical data of sonidegib and its 1,3-cuneane isostere 190 [71]. aSolubility was to...
Figure 28: Exemplary polysubstituted scaffolds related to disubstituted scaffolds suggested as isosteres of or...
An efficient metal-free and catalyst-free C–S/C–O bond-formation strategy: synthesis of pyrazole-conjugated thioamides and amides
- Shubham Sharma,
- Dharmender Singh,
- Sunit Kumar,
- Vaishali,
- Rahul Jamra,
- Naveen Banyal,
- Deepika,
- Chandi C. Malakar and
- Virender Singh
Beilstein J. Org. Chem. 2023, 19, 231–244, doi:10.3762/bjoc.19.22
- linkage is present in several naturally occurring compounds and it is also one of the most productive functional groups in current pharmaceutical drugs [50][51]. As prime examples; atorvastatin [52], valsartan [53] and N-cyclohexylethyl-ETAsV are successfully utilized to treat various life challenging
Graphical Abstract
Figure 1: Representative drug molecules based on pyrazole, thioamide, and amide derivatives.
Figure 2: Previous and present findings for the synthesis of thioamide derivatives.
Scheme 1: Synthesis of pyrazole C-3-tethered thioamides.
Scheme 2: Synthesis of pyrazole C-4-tethered thioamides.
Scheme 3: Metal- and catalyst-free preparation of pyrazole C-5-linked thioamide conjugates.
Scheme 4: Synthesis of 4-iodopyrazole C-3-tethered thioamides.
Scheme 5: Gram-scale scope of the current protocol.
Scheme 6: Control experiment.
Scheme 7: H2O2-mediated synthesis of pyrazole-pyridine conjugates with amide tethers.
Scheme 8: Synthesis of pyrazole-pyridine conjugates 9F and 10F having amide tethers.
Scheme 9: A tentative mechanism for the formation of pyrazole conjugates with thioamide and amide linkage.
Heterogeneous Pd catalysts as emulsifiers in Pickering emulsions for integrated multistep synthesis in flow chemistry
- Katharina Hiebler,
- Georg J. Lichtenegger,
- Manuel C. Maier,
- Eun Sung Park,
- Renie Gonzales-Groom,
- Bernard P. Binks and
- Heidrun Gruber-Woelfler
Beilstein J. Org. Chem. 2018, 14, 648–658, doi:10.3762/bjoc.14.52
- step in the synthesis of the targeted APIs valsartan and sacubitril. An immobilised enzyme will accomplish the final product formation via hydrolysis. In order to create a large interfacial area for the catalytic reactions and to keep the reagents separated until required, the catalyst particles are
- on the planned realisation of the integrated multistep continuous flow synthesis of valsartan and sacubitril within the frame of the ONE-FLOW project is given. The compounds are well known as APIs in a combination drug for the treatment of hypertension and chronic heart failure (Entresto®, Novartis
- potential for realising other reactions of interest to produce pharmaceutical and fine chemical intermediates in continuous flow, including the multistep synthesis of valsartan (1) and sacubitril (2). In addition to the approach with the compartmentalised catalysts in Pickering emulsions and thus the usage
Graphical Abstract
Figure 1: Targeted integrated multistep synthesis of valsartan (1) and sacubitril (2).
Scheme 1: Suzuki–Miyaura coupling of phenylboronic acid 3 with various bromoarenes 4a–e (a: R1 = H, R2 = CH3; ...
Figure 2: Particle size distribution of Ce0.495Sn0.495Pd0.01O2–δ after size reduction via milling and separat...
Figure 3: Optical microscope images of fresh aqueous dispersions, 0.05 wt %, of (a) Ce0.495Sn0.495Pd0.01O2–δ ...
Figure 4: Photos of vessels containing cyclohexane-in-water emulsions stabilised by particles of Ce0.495Sn0.4...
Figure 5: Optical microscopy images of cyclohexane-in-water emulsions of Figure 4 after one month for particle concen...
Figure 6: (top) Mean emulsion droplet diameter after 30 min as a function of particle concentration for syste...
Figure 7: Mean particle diameter in aqueous dispersions as a function of Ce0.495Sn0.495Pd0.01O2–δ concentrati...
Figure 8: Variation of the zeta potential and pH value of aqueous dispersions of Ce0.495Sn0.495Pd0.01O2–δ par...
Figure 9: (a) Appearance of octane-in-water emulsions with time at 0.05 wt % of Ce0.495Sn0.495Pd0.01O2–δ (lef...
Figure 10: (a) Variation of droplet diameter with particle concentration for octane-in-water emulsions stabili...
Figure 11: (a) Variation of droplet diameter with particle concentration for toluene-in-water emulsions stabil...
Consecutive hydrazino-Ugi-azide reactions: synthesis of acylhydrazines bearing 1,5-disubstituted tetrazoles
- Angélica de Fátima S. Barreto,
- Veronica Alves dos Santos and
- Carlos Kleber Z. Andrade
Beilstein J. Org. Chem. 2017, 13, 2596–2602, doi:10.3762/bjoc.13.256
- pharmacological activities. For instance, cilostazol (anti-inflammatory), pentylenetetrazol (circulatory and respiratory stimulant) and nojiritetrazole (antidiabetic) are drugs containing the 1,5-disubstituted tetrazole nucleus, along with the pharmaceutically important tetrazoles losartan and valsartan, which
Graphical Abstract
Figure 1: Tetrazole-containing drugs.
Scheme 1: Synthesis of acylhydrazino bis(1,5-disubstituted tetrazoles) through two hydrazino-Ugi-azide reacti...
Scheme 2: Synthesis of hydrazides 2a–c. Reagents and conditions: (i) N2H4·H2O, EtOH, reflux, 2–3 h; (ii) CH3I...
Scheme 3: Synthesis of acylhydrazino 1,5-disubstituted tetrazoles 10a–h through multicomponent reactions invo...
Scheme 4: Synthesis of acylhydrazino 1,5-disubstituted tetrazoles 10i–m through multicomponent reactions invo...
Scheme 5: Synthesis of acylhydrazino bis(1,5-disubstituted tetrazoles) 12a–d.
Scheme 6: Possible postmodification reactions of the acylhydrazino bis(1,5-disubstituted tetrazoles) 12a–d.
An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals
- Marcus Baumann,
- Ian R. Baxendale,
- Steven V. Ley and
- Nikzad Nikbin
Beilstein J. Org. Chem. 2011, 7, 442–495, doi:10.3762/bjoc.7.57
- structure, mutation studies have shown that the AT2 antagonists such as losartan bind to an active site located within the membrane-bound part of the receptor, which is different to that of the peptide agonist. Further studies led to the discovery of valsartan, where the imidazole ring of losartan is
Graphical Abstract
Figure 1: Structures of atorvastatin and other commercial statins.
Figure 2: Structure of compactin.
Scheme 1: Synthesis of pentasubstituted pyrroles.
Scheme 2: [3 + 2] Cycloaddition to prepare 5-isopropylpyrroles.
Scheme 3: Regiospecific [3 + 2] cycloaddition to prepare the pyrrole scaffold.
Scheme 4: Formation of the pyrrole core of atorvastatin via [3 + 2] cycloaddition.
Scheme 5: Formation of pyrrole 33 via the Paal–Knorr reaction.
Scheme 6: Convergent synthesis towards atorvastatin.
Figure 3: Binding pocket of sunitinib in the TRK KIT.
Scheme 7: Synthesis of sunitinib.
Scheme 8: Alternative synthesis of sunitinib.
Scheme 9: Key steps in the syntheses of sumatriptan and zolmitriptan.
Scheme 10: Introduction of the N,N-dimethylaminoethyl side chain.
Scheme 11: Japp–Klingemann reaction in the synthesis of sumatriptan.
Scheme 12: Synthesis of the intermediate sulfonyl chlorides 62 and 63.
Scheme 13: Alternative introduction of the sulfonamide.
Scheme 14: Negishi-type coupling to benzylic sulfonamides.
Scheme 15: Heck reaction used to introduce the sulfonamide side chain of naratriptan.
Scheme 16: Synthesis of the oxazolinone appendage of zolmitriptan.
Scheme 17: Grandberg indole synthesis used in the preparation of rizatriptan.
Scheme 18: Improved synthesis of rizatriptan.
Scheme 19: Larock-type synthesis of rizatriptan.
Scheme 20: Synthesis of eletriptan.
Scheme 21: Heck coupling for the indole system in eletriptan.
Scheme 22: Attempted Fischer indole synthesis of elatriptan.
Scheme 23: Successful Fischer indole synthesis for eletriptan.
Scheme 24: Mechanistic rationale for the Bischler–Möhlau reaction.
Scheme 25: Bischler-type indole synthesis used in the fluvastatin sodium synthesis.
Scheme 26: Palladium-mediated synthesis of ondansetron.
Scheme 27: Fischer indole synthesis of ondansetron.
Scheme 28: Optimised Pictet–Spengler reaction towards tadalafil.
Figure 4: Structures of carvedilol 136 and propranolol 137.
Scheme 29: Synthesis of the carbazole core of carvedilol.
Scheme 30: Alternative syntheses of 4-hydroxy-9H-carbazole.
Scheme 31: Convergent synthesis of etodolac.
Scheme 32: Alternative synthesis of etodolac.
Figure 5: Structures of imidazole-containing drugs.
Scheme 33: Synthesis of functionalised imidazoles towards losartan.
Scheme 34: Direct synthesis of the chlorinated imidazole in losartan.
Scheme 35: Synthesis of trisubstituted imidazoles.
Scheme 36: Preparation of the imidazole ring in olmesartan.
Scheme 37: Synthesis of ondansetron.
Scheme 38: Alternative route to ondansetron and its analogues.
Scheme 39: Proton pump inhibitors and synthesis of esomeprazole.
Scheme 40: Synthesis of benzimidazole core pantoprazole.
Figure 6: Structure of rabeprazole 194.
Scheme 41: Synthesis of candesartan.
Scheme 42: Alternative access to the candesartan key intermediate 216.
Scheme 43: .Medicinal chemistry route to telmisartan.
Scheme 44: Improved synthesis of telmisartan.
Scheme 45: Synthesis of zolpidem.
Scheme 46: Copper-catalysed 3-component coupling towards zolpidem.
Figure 7: Structure of celecoxib.
Scheme 47: Preparation of celecoxib.
Scheme 48: Alternative synthesis of celecoxib.
Scheme 49: Regioselective access to celecoxib.
Scheme 50: Synthesis of pazopanib.
Scheme 51: Syntheses of anastrozole, rizatriptan and letrozole.
Scheme 52: Regioselective synthesis of anastrozole.
Scheme 53: Triazine-mediated triazole formation towards anastrozole.
Scheme 54: Alternative routes to 1,2,4-triazoles.
Scheme 55: Initial synthetic route to sitagliptin.
Figure 8: Binding of sitagliptin within DPP-IV.
Scheme 56: The process route to sitagliptin key intermediate 280.
Scheme 57: Synthesis of maraviroc.
Scheme 58: Synthesis of alprazolam.
Scheme 59: The use of N-nitrosoamidine derivatives in the preparation of fused benzodiazepines.
Figure 9: Structures of itraconazole, ravuconazole and voriconazole.
Scheme 60: Synthesis of itraconazole.
Scheme 61: Synthesis of rufinamide.
Scheme 62: Representative tetrazole formation in valsartan.
Figure 10: Structure of tetrazole containing olmesartan, candesartan and irbesartan.
Scheme 63: Early stage introduction of the tetrazole in losartan.
Scheme 64: Synthesis of cilostazol.
Figure 11: Structure of cefdinir.
Scheme 65: Semi-synthesis of cefdinir.
Scheme 66: Thiazole syntheses towards ritonavir.
Scheme 67: Synthesis towards pramipexole.
Scheme 68: Alternative route to pramipexole.
Scheme 69: Synthesis of famotidine.
Scheme 70: Efficient synthesis of the hyperuricemic febuxostat.
Scheme 71: Synthesis of ziprasidone.
Figure 12: Structure of mometasone.
Scheme 72: Industrial access to 2-furoic acid present in mometasone.
Scheme 73: Synthesis of ranitidine from furfuryl alcohol.
Scheme 74: Synthesis of nitrofurantoin.
Scheme 75: Synthesis of benzofuran.
Scheme 76: Synthesis of amiodarone.
Scheme 77: Synthesis of raloxifene.
Scheme 78: Alternative access to the benzo[b]thiophene core of raloxifene.
Scheme 79: Gewald reaction in the synthesis of olanzapine.
Scheme 80: Alternative synthesis of olanzapine.
Figure 13: Access to simple thiophene-containing drugs.
Scheme 81: Synthesis of clopidogrel.
Scheme 82: Pictet–Spengler reaction in the preparation of tetrahydrothieno[3,2-c]pyridine (422).
Scheme 83: Alternative synthesis of key intermediate 422.
Figure 14: Co-crystal structures of timolol (left) and carazolol (right) in the β-adrenergic receptor.
Scheme 84: Synthesis of timolol.
Scheme 85: Synthesis of tizanidine 440.
Scheme 86: Synthesis of leflunomide.
Scheme 87: Synthesis of sulfamethoxazole.
Scheme 88: Synthesis of risperidone.
Figure 15: Relative abundance of selected transformations.
Figure 16: The abundance of heterocycles within top 200 drugs (5-membered rings).
A short and efficient synthesis of valsartan via a Negishi reaction
- Samir Ghosh,
- A. Sanjeev Kumar and
- G. N. Mehta
Beilstein J. Org. Chem. 2010, 6, No. 27, doi:10.3762/bjoc.6.27
- Samir Ghosh A. Sanjeev Kumar G. N. Mehta Applied Chemistry Department, S.V. National Institute of Technology, Surat-395 007, India 10.3762/bjoc.6.27 Abstract An efficient synthesis of the angiotensin-II inhibitor valsartan (Diovan®) is presented. Directed ortho-metalation of 5-phenyl-1-trityl-1H
- -tetrazole (6) and its Negishi coupling with aryl bromide 5 are the key steps of the synthesis. This method overcomes many of the drawbacks associated with previously reported syntheses. Keywords: antihypertensive therapy; aryl bromide; Negishi coupling; tetrazole; valsartan; Introduction Valsartan (Figure
- inhibiting the excretion of sodium by the kidneys, inhibiting norephedrine re-uptake and stimulating aldosterone biosynthesis. Valsartan [2] is therefore a non-peptide AT-II antagonist. By inhibiting the actions of AT-II on its receptors, valsartan prevents the increase of blood pressure produced by the
Graphical Abstract
Figure 1: Valsartan.
Scheme 1: Retrosynthetic analysis of 8.
Scheme 2: (a) Et3N, CH2Cl2, 0 °C, 95%; (b) NaH, THF, 70%; (c) n-BuLi, 25 °C, THF, anhyd ZnCl2, −20 °C, Q-phos...
A convenient catalyst system for microwave accelerated cross- coupling of a range of aryl boronic acids with aryl chlorides
- Matthew L. Clarke,
- Marcia B. France,
- Jose A. Fuentes,
- Edward J. Milton and
- Geoffrey J. Roff
Beilstein J. Org. Chem. 2007, 3, No. 18, doi:10.1186/1860-5397-3-18
- -phenyl boronic acid and 4-formyl boronic acid was investigated, since products 3 and 4 are potential intermediates in the synthesis of the clinically used drugs, Losartan and Valsartan respectively. [28][29] Under conventional heating conditions, attempts to couple 4-formyl benzene boronic acid to 2
Graphical Abstract
Scheme 1: Catalysts used in this study and microwave accelerated cross-coupling of functionalised boronic aci...
Scheme 2: Microwave accelerated cross-coupling of a range of boronic acids with 4-chloroacetophenone.
Scheme 3: Competition experiment demonstrating the inhibitory effect of 2,3,6-trifluorophenyl boronic acid on...
Scheme 4: Stoichiometric reactions between fluorinated boronic acids and [Pd(dppf)Cl2].
